Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Abstract
Abstracts
Author Reply
Author's Reply
Book Review
Brief Communication
Case Report
Case Series
Commentary
Continuing Medical Education
Diagnosis
Down the Memory Lane
Editorial
Editorial Board
EDITORIAL BOARD 2026-41-3
Erratum
Faculty
Free papers: Oral Session
Free papers: Poster Session
From Editor's desk
From The Chair, Scientific Committee
Guest Editorial
Image Challenge
In Memoriam
Interesting Image
Interesting Images
Invited Review
Letter to Editor
Letter to the Editor
Letters to Editor
Letters to the Editor
Message
Message by President Elect, SNM, India
Message by President, SNM, India
Messages
Obituary
Oral
ORAL PRESENTATION
Original Article
Pictorial Essay
Pictorial Teaching Essay
POSTER PRESENTATION
President's Message
Presidents’ Wall of Fame
Review
Review Article
Schedule for Paper Presentations
Scientific Program
Secretary's Message
Short Communication
SNM India Guidelines 1.0
SNMI Guidelines
Technical Communication
Technical Note
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Abstract
Abstracts
Author Reply
Author's Reply
Book Review
Brief Communication
Case Report
Case Series
Commentary
Continuing Medical Education
Diagnosis
Down the Memory Lane
Editorial
Editorial Board
EDITORIAL BOARD 2026-41-3
Erratum
Faculty
Free papers: Oral Session
Free papers: Poster Session
From Editor's desk
From The Chair, Scientific Committee
Guest Editorial
Image Challenge
In Memoriam
Interesting Image
Interesting Images
Invited Review
Letter to Editor
Letter to the Editor
Letters to Editor
Letters to the Editor
Message
Message by President Elect, SNM, India
Message by President, SNM, India
Messages
Obituary
Oral
ORAL PRESENTATION
Original Article
Pictorial Essay
Pictorial Teaching Essay
POSTER PRESENTATION
President's Message
Presidents’ Wall of Fame
Review
Review Article
Schedule for Paper Presentations
Scientific Program
Secretary's Message
Short Communication
SNM India Guidelines 1.0
SNMI Guidelines
Technical Communication
Technical Note
View/Download PDF
Interesting Image
41 (
3
); 414-416
doi:
10.25259/IJNM_156_25

Translate:

Tumour Retention of Lu-177 FAPI-2286 in Recurrent Glioblastoma – A Proof of Concept

Author affiliations
Department of Nuclear Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Department of Neurosurgery, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Article History
Corresponding author(s)

*Corresponding author: Nishikant Avinash Damle, Department of Nuclear Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India. nkantdamle@gmail.com

Article tools · PDF & citations

Abstract

Glioblastoma multiforme (GBM) is a highly aggressive primary brain tumour. There are very few and dissatisfactory treatment options for recurrence. Ga-68 fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography provides higher tumour-to-background contrast. We present the case of a 44-year-old male with recurrent GBM who underwent a tumour retention study with Lu-177 FAPI-2286. Serial whole-body planar imaging demonstrated tumour tracer retention up to day 7 postinjection, with tumour-to-background ratios peaking at days 2–4 and remaining favourable thereafter. This case highlights the prospect of Lu-177 FAPI-2286 as a therapeutic agent in recurrent GBM.

Keywords

  • Glioblastoma
  • Lu-177 fibroblast activation protein inhibitor
  • Neuro-oncology
  • Radionuclide retention
  • Theranostics
Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Bishnoi K, Damle NA, Tandon V, Priyanka GB, Tripathi M, Shamim SA, et al. Tumour Retention of Lu-177 FAPI-2286 in Recurrent Glioblastoma – A Proof of Concept. Indian J Nucl Med. 2026;41:414-6. doi: 10.25259/IJNM_156_25.

A 44-year-old male with recurrent left frontoparietotemporal glioblastoma, who showed an intense fibroblast activation protein inhibitor (FAPI) avidity on Ga-68 FAPI positron emission tomography/computed tomography, underwent a low- dose (~5 mCi) Lu-177 FAPI-2286 tumour retention study to evaluate the feasibility of Lu-177 FAPI-2286 as a potential therapeutic agent. Prior ethical approval was obtained from the institute ethics committee (AIIMSA4081/24.07.2025).

This biodistribution pattern demonstrates selective and sustained localisation of Lu-177 FAPI-2286 in the glioblastoma lesion, and persistence of uptake beyond 96 h [Fig 1-4], which is favourable for effective therapy. These observations align with the feasibility and early dosimetry study of Lu-177 FAPI-2286 in various solid tumours, such as sarcomas, breast, ovary, rectum, and pancreatic adenocarcinoma.[1,2] There are also clinical reports of radionuclide therapy using Lu-177 FAPI-2286 in nasopharyngeal carcinoma, radioiodine refractory papillary thyroid carcinoma, sarcomas, and breast cancer, as well as in bone pain palliation in breast cancer patients, showing a favourable response.[3-8] Literature search revealed a single case report discussing the potential use of Lu-177 FAPI therapy in glioblastoma multiforme (GBM) using DOTAGA. Glu.(FAPi) 2 peptide.[9] Our case provides initial clinical proof that theranostics based on Lu-177 FAPI-2286 are feasible in recurrent GBM.

(a-d) Whole-body planar scintigraphy images were acquired at (a) 2 h; (b) 24 h; (c) 96 h; and (d) 168 h (day 7) postinjection. The images show persistent focal tracer retention was observed in the left frontoparietotemporal region across all time points (blue arrows in a-d)
Fig 1: (a-d) Whole-body planar scintigraphy images were acquired at (a) 2 h; (b) 24 h; (c) 96 h; and (d) 168 h (day 7) postinjection. The images show persistent focal tracer retention was observed in the left frontoparietotemporal region across all time points (blue arrows in a-d)
(a) A single time point fused SPECT-CT and (b) corresponding CT images acquired at 2 hour post injection, showing tracer uptake (red arrow in a) in the lesion involving the left frontoparietal region (red arrow in b). SPECT-CT: Single photon emission computed tomography-computed tomography; CT: Computed tomography.
Fig 2: (a) A single time point fused SPECT-CT and (b) corresponding CT images acquired at 2 hour post injection, showing tracer uptake (red arrow in a) in the lesion involving the left frontoparietal region (red arrow in b). SPECT-CT: Single photon emission computed tomography-computed tomography; CT: Computed tomography.
Bar graph showing background corrected activity counts in given region of interest in tumour (blue bars) and liver (orange bars) against time (in hours). Notably, tumour activity exceeded background activity after 24 h (using liver as reference). ROI: Region of interest
Fig 3: Bar graph showing background corrected activity counts in given region of interest in tumour (blue bars) and liver (orange bars) against time (in hours). Notably, tumour activity exceeded background activity after 24 h (using liver as reference). ROI: Region of interest
The line chart between tumour-to-liver ratio (TLR) and time in hours shows that the TLR peaked between day 2 and day 4 (TLR 1.3), indicating prolonged intratumoural retention and slow washout kinetics. The tumour activity decreased on day 7 (TLR 1.1); however, retention remained favourable.
Fig 4: The line chart between tumour-to-liver ratio (TLR) and time in hours shows that the TLR peaked between day 2 and day 4 (TLR 1.3), indicating prolonged intratumoural retention and slow washout kinetics. The tumour activity decreased on day 7 (TLR 1.1); however, retention remained favourable.

Theranostic techniques that target tumour stroma and cancer-associated fibroblasts may provide a fresh approach to aggressive and recurrent glioblastoma. Future treatment trials in this high-unmet-need population can be supported by the retention findings seen here.

Author contributions:

KB: Clinical input, image analysis, data curation, literature review, manuscript writing – review, editing and approval; NAD: Concept and design, clinical input, image interpretation, manuscript review and approval; AK: Clinical and surgical input, manuscript review and approval; VT: Clinical and surgical input, manuscript review and approval; GP: Clinical input, manuscript review and approval; MT: Clinical input, manuscript review and approval; SAS: Clinical input, manuscript review and approval; MSL: Imaging acquisition and technical validation of imaging data, manuscript review & approval

Ethical approval:

Institutional Review Board approval is not required.

Declaration of patient consent:

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for her images and other clinical information to be reported in the journal. The patient understands that name and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.

Conflicts of interest:

There are no conflicts of interest.

Use of artificial intelligence (AI)-assisted technology for manuscript preparation:

The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.

Financial support and sponsorship: Nil.

References

  1. , , , , , , et al. Feasibility and therapeutic potential of [(177)Lu] Lu-FAPI-2286 in patients with advanced metastatic sarcoma. Eur J Nucl Med Mol Imaging. 2024;52:237-46.
    [CrossRef] [PubMed] [Google Scholar]
  2. , , , , , , et al. Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using (177)Lu-FAP-2286: First-in-humans results. J Nucl Med. 2022;63:415-23.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , , . 99m Tc-FAPI-46 scintigraphy and radioligand therapy ith 177 Lu-FAPI-2286 in locally advanced epithelioid sarcoma.
    [Google Scholar]
  4. , , , . 99m Tc-FAPI-46 scan and 177 Lu-FAPI-2286 treatment in a patient with nasopharyngeal carcinoma. Clin Nucl Med. 2025;50:e379-80.
    [CrossRef] [PubMed] [Google Scholar]
  5. , , , , . 177Lu-FAPI-2286 therapy in a patient with radio-iodine refractory papillary thyroid carcinoma: A favorable clinical and biochemical response. Clin Nucl Med. 2025;50:e315-6.
    [CrossRef] [PubMed] [Google Scholar]
  6. , , , , , . First experience of radionuclide therapy with 177Lu-FAPI-2286 in a patient with metastatic mediastinal sarcoma. Clin Nucl Med. 2024;49:e334-7.
    [CrossRef] [PubMed] [Google Scholar]
  7. , , , , . Favorable palliative effect of 177 Lu-FAPI-2286 in two breast cancer patients with refractory bone pains. Clin Nucl Med. 2025;50:e564-7.
    [CrossRef] [PubMed] [Google Scholar]
  8. , , , , , , et al. 177Lu-FAP-2286 in patients with advanced or metastatic solid tumors: Initial data from a phase 1/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumor activity (LuMIERE) J Nucl Med. 2022;63:2271.
    [Google Scholar]
  9. , , , , , , et al. [(177)Lu] Lu-DOTAGA.Glu(FAPi)(2) radionuclide therapy: A new treatment option for patients with glioblastoma multiforme. Nucl Med Mol Imaging. 2024;58:32-4.
    [CrossRef] [PubMed] [Google Scholar]

Article statistics


Fulltext Views
659

PDF downloads
1,290

Downloads

View/Download PDF
Download Citations
BibTeX
RIS
Show Sections